NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM) Presented New Phase 3 Sleep Disorder Data That Investors Will Watch
Axsome Therapeutics presented new Phase 3 data on AXS-12 in narcolepsy at a major sleep medicine conference.
The company also shared Phase 3 and post hoc analyses on solriamfetol related to sleep disorders such as sleep apnea.
These presentations focus on central nervous system conditions and add fresh clinical detail to Axsome Therapeutics' late stage pipeline.
Axsome Therapeutics (NasdaqGM:AXSM) is drawing attention after releasing new Phase 3 and post hoc data on AXS-12 and solriamfetol...